2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
2
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
40
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
32
Papillomavirus Vaccines
24
Human Papillomavirus Recombinant Vaccine nonavalent
12
Vaccines
11
Blood Specimen Collection
10
Data Collection
9
Colposcopy
9
Human Papillomavirus DNA Tests
8
Specimen Handling
7
Radiotherapy, Intensity-Modulated
7
Cisplatin
7
Surveys and Questionnaires
6
Educational Status
6
Early Intervention, Educational
6
Carboplatin
6
Vaginal Smears
5
Vaccines, Synthetic
5
Methods
5
Engerix-B
4
fludarabine
3
epigallocatechin gallate
3
artesunic acid
3
artemisinin
3
Watchful Waiting
3
Polymerase Chain Reaction
3
Patient Navigation
3
Paclitaxel
3
Observation
3
Mass Screening
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Papillomavirus Infections
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts